[A19-32] Radium-223 dichloride (mCRPC) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Last updated 15.07.2019
Project no.:
A19-32
Commission:
Commission awarded on 03.04.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with metastatic castration-resistant prostate cancer and symptomatic bone metastases (without visceral metastases) whose disease has progressed after several systemic treatments or for whom no other systemic treatment is suitable
Added benefit is not proven due to a lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A14-02 | Radium-223-dichloride - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2019-10-17 A G-BA decision was published.